Masimo Corporation (0JZ2.L)
USD 153.06
(-2.48%)
USD 153.06
(-2.48%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 136.5 Million USD | -21.76% |
| 2022 | 210 Million USD | -23.86% |
| 2021 | 275.82 Million USD | 7.82% |
| 2020 | 255.82 Million USD | 15.64% |
| 2019 | 221.21 Million USD | 6.33% |
| 2018 | 208.04 Million USD | 5.41% |
| 2017 | 197.36 Million USD | -53.1% |
| 2016 | 420.77 Million USD | 249.91% |
| 2015 | 120.25 Million USD | 16.17% |
| 2014 | 103.51 Million USD | 29.85% |
| 2013 | 79.71 Million USD | -6.46% |
| 2012 | 85.22 Million USD | -1.48% |
| 2011 | 86.5 Million USD | -17.52% |
| 2010 | 104.87 Million USD | 27.38% |
| 2009 | 82.32 Million USD | 15.67% |
| 2008 | 71.17 Million USD | 5.92% |
| 2007 | 67.19 Million USD | 46.79% |
| 2006 | 45.77 Million USD | 180.03% |
| 2005 | 16.34 Million USD | -76.43% |
| 2004 | 69.35 Million USD | 1171.48% |
| 2003 | -6.47 Million USD | -8847.3% |
| 2002 | 74 Thousand USD | 0.0% |
| 1999 | -12.9 Million USD | -72.0% |
| 1998 | -7.5 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 30.1 Million USD | 6.36% |
| 2024 Q1 | 34 Million USD | -47.61% |
| 2024 Q2 | 28.3 Million USD | -16.76% |
| 2023 Q4 | 64.9 Million USD | 157.54% |
| 2023 Q3 | 25.2 Million USD | -13.99% |
| 2023 Q1 | 38 Million USD | -48.16% |
| 2023 Q2 | 29.3 Million USD | -22.89% |
| 2023 FY | 164.3 Million USD | -21.76% |
| 2022 Q4 | 73.3 Million USD | -6.15% |
| 2022 Q1 | 59.74 Million USD | -22.82% |
| 2022 Q2 | -48.66 Million USD | -181.46% |
| 2022 Q3 | 78.1 Million USD | 260.48% |
| 2022 FY | 210 Million USD | -23.86% |
| 2021 Q2 | 65.13 Million USD | -0.8% |
| 2021 Q1 | 65.66 Million USD | 1.18% |
| 2021 FY | 275.82 Million USD | 7.82% |
| 2021 Q3 | 67.61 Million USD | 3.8% |
| 2021 Q4 | 77.41 Million USD | 14.49% |
| 2020 FY | 255.82 Million USD | 15.64% |
| 2020 Q4 | 64.89 Million USD | 8.71% |
| 2020 Q3 | 59.69 Million USD | -4.05% |
| 2020 Q2 | 62.22 Million USD | -9.84% |
| 2020 Q1 | 69.01 Million USD | 12.11% |
| 2019 Q3 | 51.63 Million USD | -0.72% |
| 2019 FY | 221.21 Million USD | 6.33% |
| 2019 Q1 | 56.02 Million USD | 3.93% |
| 2019 Q2 | 52 Million USD | -7.17% |
| 2019 Q4 | 61.55 Million USD | 19.22% |
| 2018 Q3 | 48.64 Million USD | -5.76% |
| 2018 FY | 208.04 Million USD | 5.41% |
| 2018 Q1 | 53.88 Million USD | -9.17% |
| 2018 Q2 | 51.61 Million USD | -4.22% |
| 2018 Q4 | 53.9 Million USD | 10.82% |
| 2017 Q2 | 46.86 Million USD | 8.5% |
| 2017 Q4 | 59.32 Million USD | 23.65% |
| 2017 Q1 | 43.19 Million USD | -86.08% |
| 2017 FY | 197.36 Million USD | -53.1% |
| 2017 Q3 | 47.97 Million USD | 2.36% |
| 2016 FY | 420.77 Million USD | 249.91% |
| 2016 Q3 | 36.6 Million USD | 0.48% |
| 2016 Q1 | 37.33 Million USD | 1.21% |
| 2016 Q2 | 36.42 Million USD | -2.43% |
| 2016 Q4 | 310.4 Million USD | 747.99% |
| 2015 FY | 120.25 Million USD | 16.17% |
| 2015 Q4 | 36.89 Million USD | 31.1% |
| 2015 Q3 | 28.14 Million USD | 1.07% |
| 2015 Q2 | 27.84 Million USD | 1.69% |
| 2015 Q1 | 27.37 Million USD | -16.14% |
| 2014 Q3 | 22.26 Million USD | 20.99% |
| 2014 Q1 | 30.19 Million USD | 138.62% |
| 2014 Q4 | 32.64 Million USD | 46.61% |
| 2014 FY | 103.51 Million USD | 29.85% |
| 2014 Q2 | 18.4 Million USD | -39.04% |
| 2013 Q4 | 12.65 Million USD | -39.0% |
| 2013 Q3 | 20.74 Million USD | -10.51% |
| 2013 Q2 | 23.18 Million USD | 0.17% |
| 2013 FY | 79.71 Million USD | -6.46% |
| 2013 Q1 | 23.14 Million USD | 9.33% |
| 2012 Q3 | 17.95 Million USD | -17.19% |
| 2012 FY | 85.22 Million USD | -1.48% |
| 2012 Q4 | 21.16 Million USD | 17.9% |
| 2012 Q1 | 22.91 Million USD | 11.59% |
| 2012 Q2 | 21.67 Million USD | -5.38% |
| 2011 Q1 | 25.19 Million USD | 17.54% |
| 2011 Q3 | 19.17 Million USD | -11.25% |
| 2011 Q4 | 20.53 Million USD | 7.08% |
| 2011 FY | 86.5 Million USD | -17.52% |
| 2011 Q2 | 21.6 Million USD | -14.25% |
| 2010 Q4 | 21.43 Million USD | -0.79% |
| 2010 FY | 104.87 Million USD | 27.38% |
| 2010 Q1 | 40.63 Million USD | 90.2% |
| 2010 Q3 | 21.6 Million USD | 4.37% |
| 2010 Q2 | 20.7 Million USD | -49.06% |
| 2009 Q1 | 20.12 Million USD | 3.25% |
| 2009 Q4 | 21.36 Million USD | 2.55% |
| 2009 Q3 | 20.83 Million USD | 4.12% |
| 2009 FY | 82.32 Million USD | 15.67% |
| 2009 Q2 | 20 Million USD | -0.56% |
| 2008 Q1 | 14.34 Million USD | -13.67% |
| 2008 Q4 | 19.48 Million USD | -3.33% |
| 2008 Q3 | 20.16 Million USD | 17.36% |
| 2008 Q2 | 17.17 Million USD | 19.72% |
| 2008 FY | 71.17 Million USD | 5.92% |
| 2007 Q3 | 16.87 Million USD | -4.33% |
| 2007 Q1 | 15.14 Million USD | -89.4% |
| 2007 Q2 | 17.63 Million USD | 16.45% |
| 2007 FY | 67.19 Million USD | 46.79% |
| 2007 Q4 | 16.61 Million USD | -1.51% |
| 2006 FY | 45.77 Million USD | 180.03% |
| 2006 Q2 | 58.34 Million USD | 18.33% |
| 2006 Q3 | 58.34 Million USD | 0.0% |
| 2006 Q4 | 142.94 Million USD | 145.0% |
| 2006 Q1 | 49.3 Million USD | 171.34% |
| 2005 Q1 | 26.97 Million USD | 0.0% |
| 2005 FY | 16.34 Million USD | -76.43% |
| 2005 Q2 | 26.97 Million USD | 0.0% |
| 2005 Q3 | 26.97 Million USD | 0.0% |
| 2005 Q4 | -69.11 Million USD | -356.23% |
| 2004 FY | 69.35 Million USD | 1171.48% |
| 2003 FY | -6.47 Million USD | -8847.3% |
| 2002 FY | 74 Thousand USD | 0.0% |
| 1999 Q3 | -2.6 Million USD | 0.0% |
| 1999 FY | -12.9 Million USD | -72.0% |
| 1999 Q4 | -4.3 Million USD | -65.38% |
| 1998 FY | -7.5 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Phreesia, Inc. | -131.77 Million USD | 203.587% |
| Accuray Incorporated | 504 Thousand USD | -26983.333% |
| Align Technology, Inc. | 643.33 Million USD | 78.783% |
| Elevance Health Inc. | 133.96 Billion USD | 99.898% |
| AxoGen, Inc. | -21.46 Million USD | 736.008% |
| Boston Scientific Corporation | 2.34 Billion USD | 94.174% |
| CVS Health Corporation | 13.74 Billion USD | 99.007% |
| Cardinal Health, Inc. | 1.24 Billion USD | 89.019% |
| Centene Corporation | 2.93 Billion USD | 95.341% |
| DaVita Inc. | 1.6 Billion USD | 91.484% |
| HCA Healthcare, Inc. | 9.62 Billion USD | 98.582% |
| Hologic, Inc. | 970.2 Million USD | 85.931% |
| Humana Inc. | 4.01 Billion USD | 96.599% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 87.558% |
| Laboratory Corporation of America Holdings | 725.6 Million USD | 81.188% |
| McKesson Corporation | 3.9 Billion USD | 96.508% |
| Patterson Companies, Inc. | 252.92 Million USD | 46.031% |
| Quest Diagnostics Incorporated | 1.26 Billion USD | 89.184% |
| ResMed Inc. | 1.31 Billion USD | 89.658% |
| Henry Schein, Inc. | 615 Million USD | 77.805% |
| Teladoc Health, Inc. | -248.55 Million USD | 154.918% |
| Universal Health Services, Inc. | 1.17 Billion USD | 88.387% |
| Veeva Systems Inc. | 429.33 Million USD | 68.207% |
| Baxter International Inc. | 390 Million USD | 65.0% |
| Becton, Dickinson and Company | 2.11 Billion USD | 93.534% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 92.274% |
| Danaher Corporation | 5.38 Billion USD | 97.463% |
| Stryker Corporation | 3.88 Billion USD | 96.489% |
| Medtronic plc | 5.14 Billion USD | 97.346% |